Improving prescription drug labelling in the US
This article was originally published in SRA
Executive Summary
Cathleen O’Connell, Paul Imm and Sandra Kuhn explain how the Food and Drug Administration and other stakeholders are working to improve the quality of content, the timeliness of implementation and the availability of written drug information.